Major drugmaker loses $27 billion in market value after failed trial
MarketWatch· Nora Redmond· Jul 9, 2026 · 12:03 PM
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 5 hours ago
How to downsize like a pro — and free yourself from being a ‘prisoner of your possessions’
Seven tips for painlessly moving in retirement.
MarketWatch
marketsabout 5 hours ago
Florida is voting on whether to slash property taxes. Here’s who it would benefit — and hurt.
Amendment 3’s passage could add momentum to other states’ efforts to slash property taxes
MarketWatch
marketsabout 6 hours ago
The options market is reminding investors there’s a cure for rising bond yields — higher yields
The MOVE Index — the Treasury market’s “fear gauge” — has reached heights that in the past suggested yields may have peaked, at least for now.
MarketWatch